Search - tctmd.com

Displaying 241 - 260 of 302

Presentation TCT 2013

Can the Rate of Acute Stent Thrombosis with Bivalirudin Anticoagulation During Primary PCI in STEMI be Reduced with Modified Pharmacologic Regimens?

Presenter: Andreas Baumbach, Harold Dauerman, Bernardo Cortese, Martial Hamon, Jayne Prats, Efthymios Deliargyris, Roxana Mehran, Gregg Stone

January 31, 2013

News Daily News

Una Dosis Alta de Aspirina tras una PCI Primaria aumenta las Hemorragias No observandose Beneficio Isquémico alguno

L.A. McKeown

December 19, 2012

News Daily News

High-Dose Aspirin After Primary PCI Increases Bleeding with No Ischemic Benefit

L.A. McKeown

December 19, 2012

News Daily News

Un Test Podría Detectar qué Pacientes STEMI corren Riesgo de sufrir Nefropatía por Contraste tras someterse a una PCI

Jason Kahn

December 03, 2012

News Daily News

Test May Detect STEMI Patients at Risk for Contrast Nephropathy After PCI

Jason Kahn

December 03, 2012

Presentation TCT 2012

Contrast-Induced Acute Kidney Injury: Have We Reached a Ceiling in Prevention?

Presenter: Roxana Mehran

October 26, 2012

Presentation TCT 2012

Proposals for New Short-Term DAPT Use Trials After DES

Presenter: Roxana Mehran

October 25, 2012

Presentation TCT 2012

Debate: Bivalirudin Is the Preferred Anticoagulant Strategy During STEMI!

Presenter: Roxana Mehran

October 25, 2012

Presentation TCT 2012

Continuity Equation: Streamlining Processes from Pre-Market Approval to Post-Market Surveillance

Presenter: Roxana Mehran

October 25, 2012

Presentation TCT 2012

Factor IXa Inhibition (Aptamer) Update

Presenter: Roxana Mehran

October 24, 2012

Presentation TCT 2012

A View to Future Trials: HORIZONS-AMI II and Others

Presenter: Roxana Mehran

October 24, 2012

Presentation TCT 2012

Modeling the Risk of Stroke and Bleeding in Atrial Fibrillation: What Are the Optimal Risk Scores?

Presenter: Roxana Mehran

October 23, 2012

Presentation TCT 2012

In-Stent Restenosis: Mechanisms, Predictors, and Treatment

Presenter: Roxana Mehran

October 23, 2012

News Conference News TCT 2012

DAPT Cessation Within 1 Year Increased Risk for Major Adverse Events

October 23, 2012

Presentation TCT 2012

Chronic Kidney Disease, Contrast Agents, and Radiocontrast Nephropathy

Presenter: Roxana Mehran

October 23, 2012

Presentation TCT 2012

PARIS 1-Year: Impact of DAPT Cessation and Non-adherence on Adverse Events Following PCI

Presenter: Roxana Mehran

October 22, 2012

Presentation TCT 2012

Dedicated Bifurcation Stents: Minvasys Nile Program Update

Presenter: Roxana Mehran

October 22, 2012

Presentation TCT 2012

Choice of Antiplatelet Therapies in ACS/STEMI

Presenter: Roxana Mehran

October 22, 2012

Presentation TCT 2012

US Perspective

Presenter: Roxana Mehran

October 22, 2012

Presentation TCT 2012

Randomized Trials vs. Observational Studies: Advantages and Pitfalls

Presenter: Roxana Mehran

October 22, 2012

Advertisement

Can the Rate of Acute Stent Thrombosis with Bivalirudin Anticoagulation During Primary PCI in STEMI be Reduced with Modified Pharmacologic Regimens?

Una Dosis Alta de Aspirina tras una PCI Primaria aumenta las Hemorragias No observandose Beneficio Isquémico alguno

High-Dose Aspirin After Primary PCI Increases Bleeding with No Ischemic Benefit

Un Test Podría Detectar qué Pacientes STEMI corren Riesgo de sufrir Nefropatía por Contraste tras someterse a una PCI

Test May Detect STEMI Patients at Risk for Contrast Nephropathy After PCI

Contrast-Induced Acute Kidney Injury: Have We Reached a Ceiling in Prevention?

Proposals for New Short-Term DAPT Use Trials After DES

Debate: Bivalirudin Is the Preferred Anticoagulant Strategy During STEMI!

Continuity Equation: Streamlining Processes from Pre-Market Approval to Post-Market Surveillance

Factor IXa Inhibition (Aptamer) Update

A View to Future Trials: HORIZONS-AMI II and Others

Modeling the Risk of Stroke and Bleeding in Atrial Fibrillation: What Are the Optimal Risk Scores?

In-Stent Restenosis: Mechanisms, Predictors, and Treatment

DAPT Cessation Within 1 Year Increased Risk for Major Adverse Events

Chronic Kidney Disease, Contrast Agents, and Radiocontrast Nephropathy

PARIS 1-Year: Impact of DAPT Cessation and Non-adherence on Adverse Events Following PCI

Dedicated Bifurcation Stents: Minvasys Nile Program Update

Choice of Antiplatelet Therapies in ACS/STEMI

US Perspective

Randomized Trials vs. Observational Studies: Advantages and Pitfalls

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content